SLDB Stock — Solid Biosciences Inc.: Cash, EV, Pipeline

Share price

$8.91

Market cap

$955.4M

Cash

$377.7M

Enterprise value

$577.7M

Balance sheet

Cash	$377.7M
Debt	$0.0M
Net cash	$377.7M
Enterprise value	$577.7M
Basic shares	105.1M shares
Fully diluted shares	128.7M shares
Fully diluted market cap	$1,147.1M
Cash per share	$3.59

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SLDB daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	SGT-501	Phase 1	Catecholaminergic Polymorphic Ventricular Tachycardia	—
May 2 - Jun 13	SGT-212	Phase 1	Friedreich's Ataxia (FA)	—
Feb 12 - Mar 26	SGT-003	Phase 3	Duchenne Muscular Dystrophy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

SGT-003

Phase 3 · Active Modality: gene therapy

Target Dystrophin

Indications

Duchenne muscular dystrophy (Duchenne) (Phase 3)

Catalysts

— March 2026
— Oct 2025

Status note Phase 1/2 INSPIRE DUCHENNE: first-in-human open-label single-dose trial in pediatric patients at 1E14vg/kg; positive interim data announced March 11, 2026; generally well tolerated in 53 dosed participants as of Aug 4, 2026. Phase 3 IMPACT DUCHENNE (randomized, double-blind, placebo-controlled) began screening Oct 2025.

SGT-212

Phase 1 · Active Modality: gene therapy

Target FXN

Partnerships FA212 LLC (development milestone obligation)

Indications

Friedreich's ataxia (FA) (Phase 1)

Catalysts

— Jan 2026

Status note Phase 1b FALCON: open-label multicenter trial; first participant dosed Jan 2026.

SGT-501

Phase 1 · Active Modality: gene therapy

Target CASQ2

Indications

catecholaminergic polymorphic ventricular tachycardia (CPVT) (Phase 1)

Catalysts

— Jan 2026

Status note Phase 1b ARTEMIS: open-label multicenter trial in adult participants with CPVT; screening underway as of Jan 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SGT-003
Lead indication	Duchenne Muscular Dystrophy
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07160634	Phase 3	Recruiting	Sponsor	SLDB	—	Duchenne Muscular Dystrophy	—
NCT03368742	Phase 2	Active, not recruiting	Sponsor	SLDB	—	Duchenne Muscular Dystrophy	—
NCT06138639	Phase 2	Recruiting	Sponsor	SLDB	—	Duchenne Muscular Dystrophy	—
NCT07148089	Phase 1	Recruiting	Sponsor	SLDB	—	Catecholaminergic Polymorphic Ventricular Tachycardia	—
NCT07180355	Phase 1	Recruiting	Sponsor	SLDB	—	Friedreich's Ataxia (FA)	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Solid Biosciences Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	3,892,926	+3,892,926	0.33%	2026-08-14
Ikarian Capital	42,956	-221,453	0.07%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

SLDB — Solid Biosciences Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders